A Crossover Study to Assess the Bioequivalence of Hydrocodone Bitartrate Extended-Release Tablet

Overview

The primary objective of this study is to assess the bioequivalence of two 30-mg hydrocodone bitartrate extended-release tablets and one 60-mg hydrocodone bitartrate extended-release tablet.

Full Title of Study: “A Randomized, Open-Label, 2-Period, Crossover Study to Assess the Bioequivalence of Two 30-mg and One 60-mg Hydrocodone Bitartrate Extended-Release Tablet”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Crossover Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: January 2013

Interventions

  • Drug: a 60 mg dose of the hydrocodone bitartrate extended-release tablet administered as either two 30-mg tablets (Treatment A) or one 60-mg tablet (Treatment B).
    • Each subject will receive 1 treatment during each administration period. Subjects will receive each of the 2 treatments once. There will be a minimum 14-day washout period between the 2 administrations of study drug. Treatments will be orally administered to subjects, while they are seated, at approximately 0800 (±2 hours) on the 1st day of each administration period.

Arms, Groups and Cohorts

  • Experimental: Treatment Group AB
    • Subjects in this group will receive study drug in the following sequence: Treatment A: two 30-mg hydrocodone bitartrate extended-release tablets (reference) Treatment B: one 60-mg hydrocodone bitartrate extended-release tablet (test).
  • Experimental: Treatment Group BA
    • Subjects in this group will receive study drug in the following sequence: Treatment B: one 60-mg hydrocodone bitartrate extended-release tablet (test). Treatment A: two 30-mg hydrocodone bitartrate extended-release tablets (reference).

Clinical Trial Outcome Measures

Primary Measures

  • Maximum observed plasma drug concentration (Cmax)
    • Time Frame: Approximately 5 minutes prior to study drug administration up to 72 post study drug administration.
    • To assess the bioequivalence between 30-mg tablets and one 60-mg tablet of the hydrocodone bitartrate extended-release tablet.
  • Area under the plasma drug concentration by time curve AUC 0-∞
    • Time Frame: Approximately 5 minutes prior to study drug administration up to 72 post study drug administration.
    • To assess bioequivalence between two 30-mg tablets and one 60-mg tablet of the hydrocodone bitartrate extended-release tablet.

Secondary Measures

  • Time to maximum observed plasma drug concentration (tmax)
    • Time Frame: Approximately 5 minutes prior to study drug administration up to 72 post study drug administration.
    • To characterize the pharmacokinetics of the hydrocodone bitartrate extended-release tablet.
  • AUC from time 0 to 72 hours after study drug administration (AUC0-72)
    • Time Frame: Approximately 5 minutes prior to study drug administration up to 72 post study drug administration.
    • To characterize the pharmacokinetics of the hydrocodone bitartrate extended-release tablet.
  • AUC from time 0 to the time of the last measurable drug concentration (AUC0-t)
    • Time Frame: Approximately 5 minutes prior to study drug administration up to 72 post study drug administration.
    • To characterize the pharmacokinetics of the hydrocodone bitartrate extended-release tablet.
  • Percentage extrapolation, 100x(AUC0-∞-AUC0-t)/AUC0-∞)
    • Time Frame: Approximately 5 minutes prior to study drug administration up to 72 post study drug administration.
    • To characterize the pharmacokinetics of the hydrocodone bitartrate extended-release tablet.
  • Apparent plasma terminal elimination rate constant (λz) and associated elimination half life (t½)
    • Time Frame: Approximately 5 minutes prior to study drug administration up to 72 post study drug administration.
    • To characterize the pharmacokinetics of the hydrocodone bitartrate extended-release tablet.
  • Recording of Adverse Events
    • Time Frame: From ICF signing to 48-72 hours after discharge from the study center following the last administration of the hydrocodone bitartrate extended-release tablet.
    • To characterize the safety of the hydrocodone bitartrate extended-release tablet in healthy naltrexone-blocked subjects.

Participating in This Clinical Trial

Inclusion Criteria

  • Written informed consent is obtained. – The subject can read, speak, and write in English. – The subject is a man or woman 18 through 45 years of age, with a body mass index (BMI) of 20.0 to 30.0 kg/m2, inclusive. – The subject is in good health as determined by medical and psychiatric history, physical examination, ECG, serum chemistry, hematology, urinalysis, and serology. – Women must be surgically sterile, 2 years postmenopausal, or, if of child-bearing potential, be using an acceptable method of contraception, and agree to continued use of this method for the duration of the study and for 30 days after discontinuation of study drug. Acceptable methods of contraception include abstinence or an intrauterine device (known to have a failure rate of less than 1% per year). – The subject has a negative alcohol test and urine drug screen (UDS). – The subject must be willing and able to comply with study restrictions and to remain at the study center for the required duration of each study drug period during the study. Exclusion Criteria:

  • The subject has any clinically significant uncontrolled medical conditions (treated or untreated). – The subject has a clinically significant deviation from normal in ECG or physical examination findings, as determined by the investigator or the medical monitor. – The subject has habitually consumed, within the past 2 years, more than 21 units of alcohol per week, or has a history of alcohol, narcotic, or any other substance abuse as defined by the Diagnostic and Statistical Manual of Mental Disorder, Fourth Edition, Text Revision (DSM-IV-TR, American Psychiatric Association 2000). NOTE: A unit of alcohol is equal to 1 ounce of hard liquor, 5 ounces of wine, or 8 ounces of beer. – The subject is a pregnant or lactating woman. (Any women becoming pregnant during the study will be withdrawn from the study.) – The subject has any disorder that may interfere with drug absorption, distribution, metabolism, or excretion (including gastrointestinal (GI) surgery; a history of appendectomy is allowed). – The subject has received any investigational drug within 30 days or 5 half-lives (whichever is longer) before the 1st dose of study drug, or in the case of a new chemical entity, 3 months or 5 half-lives (whichever is longer) before the 1st dose of study drug. – The subject has a known sensitivity or idiosyncratic reaction to hydrocodone or hydromorphone, their related compounds, or to any metabolites, or naltrexone, or any compound listed as being present in a study formulation. – Other exclusion criteria apply.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 45 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Teva Branded Pharmaceutical Products R&D, Inc.
  • Provider of Information About this Clinical Study
    • Sponsor

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.